MayoMobile,
Given the estimated cost of Lecanemab, what do you expect would be the Anavex Life Sciences yearly revenue, if Anavex's Blarcamesine were FDA approved and cost each recipient just half the minimum yearly cost of $9,249 for lecanemab?
Based on an (internal) initial economic assessment, Eisai said that its annual “value-based price” of lecanemab would be anywhere between $9,249 and $35,605.
Good luck and GOD bless,